WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4: C07J 41/00, 43/00, A61K 31/56 A61K 31/58, C07C 87/34, 87/455 C07D 213/38, C07F 9/24 C07F 9/22, A61K 31/13

(11) International Publication Number:

WO 87/ 02367

A2

(43) International Publication Date:

23 April 1987 (23.04.87)

(21) International Application Number:

PCT/US86/02116

(22) International Filing Date:

7 October 1986 (07.10.86)

(31) Priority Application Numbers:

788,995

843,120

(32) Priority Dates:

18 October 1985 (18.10.85) 24 March 1986 (24.03.86)

(33) Priority Country:

US

(60) Parent Applications or Grants (63) Related by Continuation

US

843,120 (CIP)

Filed on US

24 March 1986 (24.03.86) 788,995 (CIP)

Filed on

18 October 1985 (18.10.85)

(71) Applicant (for all designated States except US): THE UPJOHN COMPANY [US/US]; 301 Henricuta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors; and
(75) Inventors/Applicants (for US only): JOHNSON, Roy,
A. [US/US]: 2122 Frederick Avenue, Kalamazoo, MI
49008 (US). BUNDY, Gordon, L. [US/US]: 7622
Ravenswood Drive, Kalamazoo, MI 49002 (US).
YOUNGDALE, Gilbert, A. [US/US]: 1702 Greenbriar Drive, Portage, MI 49002 (US). MORTON, Douglas, R. [US/US]: 3128 Tattersal Road, Portage, MI
49081 (US).


(74) Agent: KOIVUNIEMI, Paul, J.; Patent Law Department, The Upjohn Company, Kalamazoo, MI 49001

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), IP, LU (European paten tent), NL (European patent), SE (European patent),

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN



(57) Abstract

Provided are cyclic hydrocarbons of Formula (I) with an aminoalkyl sidechain that are useful for treating phospholipase A2-mediated conditions, diabetes and obesity.